Ovulation suppression following subcutaneous administration of depot medroxyprogesterone acetate
Contraception: X · 2022 · 4 · 100073
DOI: 10.1016/j.conx.2022.100073 ↗Kurz gefasst
Fachartikel in der Zeitschrift Contraception: X, 2022. Verfasst von Douglas J Taylor und 5 weiteren Autor:innen. Beteiligte Einrichtung: FHI 360, Durham, NC, United States. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bill and Melinda Gates Foundation, Oregon Health and Science University, United States Agency for International Development.
Abstract (Originalsprache)
Objectives
To characterize the relationship between serum medroxyprogesterone acetate (MPA) concentrations and ovulation suppression, and to estimate the risk of ovulation for investigational subcutaneous regimens of Depo-Provera CI (Depo-Provera) and Depo-subQ Provera 104 (Depo-subQ). Study Design: We performed a secondary analysis of 2 studies that assessed the pharmacokinetics and pharmacodynamics of MPA when Depo-Provera is administered subcutaneously rather than by the labeled intramuscular route. Each woman received a single 45 mg to 300 mg subcutaneous injection of Depo-Provera, a single 104 mg subcutaneous injection of Depo-subQ, or 2 injections of Depo-subQ at 3-month intervals. We used an elevation of serum progesterone ≥4.7 ng/mL as a surrogate for ovulation and non-parametric statistical methods to assess pharmacokinetic and pharmacodynamic relationships.
Results
This analysis included 101 women with body mass index (BMI) 18 to 34 kg/m2. Return of ovulation occurred at a median MPA concentration of 0.07 ng/mL (95% CI: 0.06-0.08) and the 90th percentile was 0.10 ng/mL (95% CI: 0.09-0.14). Neither age, race, nor BMI significantly influenced this relationship. The estimated probabilities of ovulation within 4 months of a 104 mg subcutaneous injection and within 7 months of a 150 mg subcutaneous injection (6 plus a 1-month grace) were each below 2.2%.
Conclusions
The typical MPA concentration associated with loss of ovulation suppression is substantially less than the commonly cited threshold of 0.2 ng/mL. Based on our results, MPA levels would rarely be low enough to permit ovulation if the Depo-subQ reinjection interval were extended to four months or if 150 mg Depo-Provera were injected subcutaneously every 6 months.
Implications
Extending the three-month Depo-subQ reinjection interval by one month would result in a 25% reduction in yearly MPA exposure, with little risk of pregnancy. Off-label subcutaneous administration of 150 mg Depo-Provera every 6 months would be a highly effective repurposing of an excellent product, with a similar reduction in cumulative exposure.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- FHI 360, Durham, NC, United States.
- Profamilia, Biomedical Research Department, Santo Domingo, Dominican Republic.
- Department of Obstetrics and Gynecology, University of Campinas Faculty of Medical Sciences, Campinas, Brazil.
- Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR, United States.
Förderung
- Bill and Melinda Gates Foundation
- Oregon Health and Science University
- United States Agency for International Development
Zitieren
APA
Taylor, D. J., Halpern, V., Brache, V., Bahamondes, L., Jensen, J. T., & Dorflinger, L. J. (2022). Ovulation suppression following subcutaneous administration of depot medroxyprogesterone acetate. Contraception: X, 4, 100073. https://doi.org/10.1016/j.conx.2022.100073
Vancouver
Taylor DJ, Halpern V, Brache V, Bahamondes L, Jensen JT, Dorflinger LJ. Ovulation suppression following subcutaneous administration of depot medroxyprogesterone acetate. Contraception: X. 2022;4:100073. doi:10.1016/j.conx.2022.100073
BibTeX
@article{Taylor2022,
author = {Taylor, Douglas J and Halpern, Vera and Brache, Vivian and Bahamondes, Luis and Jensen, Jeffrey T and Dorflinger, Laneta J},
title = {Ovulation suppression following subcutaneous administration of depot medroxyprogesterone acetate},
journal = {Contraception: X},
year = {2022},
volume = {4},
pages = {100073},
doi = {10.1016/j.conx.2022.100073}
}
EUVIMED